BioAge Labs, Inc.

BioAge Labs, Inc.

BIOA

Get informed when a big investor buys or sells

+ Follow
Market Cap$43.7B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BioAge Labs, Inc.BioAge Labs, Inc.-4--26%--
$30.50

Target Price by Analysts

193.3% upsideBioAge Labs Target Price DetailsTarget Price
$6.75

Current Fair Value

35.1% downside

Overvalued by 35.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$43.70 Billion
Enterprise Value$43.52 Billion
Dividend Yield$- (-)
Earnings per Share$-2.24
Beta0.93
Outstanding Shares44,838,893

Return

Return on Equity-25.93%ROE
Return on Assets-23.92%
Return on Invested Capital-27.36%

Valuation & Multiples

P/E Ratio-3.98P/E Ratio
PEG-0.7PEG
Price to Sales-Price to Sales
Price to Book Ratio1.73Price to Book Ratio
Enterprise Value to Revenue3333
Enterprise Value to EBIT-579.03
Enterprise Value to Net Income-618
Total Debt to Enterprise0
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.63
Average shareholder expectation
Revenue Estimate
$1.58 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$-0.66
Average shareholder expectation
Revenue Estimate
$1.53 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1210 670.48%
Total Calls888,610 5632.97%
Total Puts107,500 1.61%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %89.47% 5.95%
Total Invested$931.41M 55.43%
Investors Holding163 15.00%

ESG Score

No data

About ProShares - GENIUS Money Market ETF

62 employees
CEO: Patrick Chalhoub

This particular fund is offered as a component within the ProShares Trust framework. Its central objective is to generate steady income, while concurrently prioritizing accessible funds and the safeguarding of investors' principal. A key...